vs
Side-by-side financial comparison of GENCOR INDUSTRIES INC (GENC) and Karyopharm Therapeutics Inc. (KPTI). Click either name above to swap in a different company.
Karyopharm Therapeutics Inc. is the larger business by last-quarter revenue ($34.1M vs $23.6M, roughly 1.4× GENCOR INDUSTRIES INC). GENCOR INDUSTRIES INC runs the higher net margin — 14.6% vs -299.9%, a 314.5% gap on every dollar of revenue. On growth, Karyopharm Therapeutics Inc. posted the faster year-over-year revenue change (11.6% vs -25.0%). Over the past eight quarters, Karyopharm Therapeutics Inc.'s revenue compounded faster (1.4% CAGR vs -23.9%).
Gencor Industries Inc is a leading manufacturer of heavy construction and infrastructure equipment, specializing in asphalt production plants, thermal combustion systems, and supporting road-building machinery. It primarily serves North American and global construction markets, supplying products to both public sector infrastructure projects and private commercial construction operators.
GENC vs KPTI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.6M | $34.1M |
| Net Profit | $3.4M | $-102.2M |
| Gross Margin | 28.7% | — |
| Operating Margin | 13.2% | -52.4% |
| Net Margin | 14.6% | -299.9% |
| Revenue YoY | -25.0% | 11.6% |
| Net Profit YoY | -9.8% | -232.0% |
| EPS (diluted) | $0.23 | $-7.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.6M | $34.1M | ||
| Q3 25 | $18.8M | $44.0M | ||
| Q2 25 | $27.0M | $37.9M | ||
| Q1 25 | $38.2M | $30.0M | ||
| Q4 24 | $31.4M | $30.5M | ||
| Q3 24 | $20.9M | $38.8M | ||
| Q2 24 | $25.6M | $42.8M | ||
| Q1 24 | $40.7M | $33.1M |
| Q4 25 | $3.4M | $-102.2M | ||
| Q3 25 | $1.9M | $-33.1M | ||
| Q2 25 | $3.8M | $-37.3M | ||
| Q1 25 | $6.1M | $-23.5M | ||
| Q4 24 | $3.8M | $-30.8M | ||
| Q3 24 | $1.5M | $-32.1M | ||
| Q2 24 | $2.6M | $23.8M | ||
| Q1 24 | $6.2M | $-37.4M |
| Q4 25 | 28.7% | — | ||
| Q3 25 | 24.2% | — | ||
| Q2 25 | 26.5% | — | ||
| Q1 25 | 29.7% | — | ||
| Q4 24 | 27.6% | — | ||
| Q3 24 | 25.6% | — | ||
| Q2 24 | 23.9% | — | ||
| Q1 24 | 30.3% | — |
| Q4 25 | 13.2% | -52.4% | ||
| Q3 25 | -1.2% | -34.6% | ||
| Q2 25 | 11.6% | -64.3% | ||
| Q1 25 | 17.0% | -110.8% | ||
| Q4 24 | 14.7% | -102.4% | ||
| Q3 24 | 5.9% | -67.8% | ||
| Q2 24 | 7.8% | -65.7% | ||
| Q1 24 | 17.4% | -101.9% |
| Q4 25 | 14.6% | -299.9% | ||
| Q3 25 | 10.2% | -75.2% | ||
| Q2 25 | 14.2% | -98.2% | ||
| Q1 25 | 16.0% | -78.2% | ||
| Q4 24 | 12.1% | -100.8% | ||
| Q3 24 | 6.9% | -82.7% | ||
| Q2 24 | 10.0% | 55.6% | ||
| Q1 24 | 15.3% | -112.8% |
| Q4 25 | $0.23 | $-7.02 | ||
| Q3 25 | $0.13 | $-3.82 | ||
| Q2 25 | $0.26 | $-4.32 | ||
| Q1 25 | $0.42 | $-2.77 | ||
| Q4 24 | $0.26 | $-2.33 | ||
| Q3 24 | $0.10 | $-3.85 | ||
| Q2 24 | $0.17 | $-2.97 | ||
| Q1 24 | $0.42 | $-4.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $147.7M | $60.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $215.2M | $-292.9M |
| Total Assets | $228.9M | $108.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $147.7M | $60.5M | ||
| Q3 25 | $136.3M | $37.7M | ||
| Q2 25 | $136.0M | $38.7M | ||
| Q1 25 | $143.7M | $38.8M | ||
| Q4 24 | $130.1M | $62.5M | ||
| Q3 24 | $115.4M | $72.8M | ||
| Q2 24 | $116.6M | $84.8M | ||
| Q1 24 | $117.1M | $30.6M |
| Q4 25 | — | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $215.2M | $-292.9M | ||
| Q3 25 | $211.8M | $-269.3M | ||
| Q2 25 | $209.9M | $-238.9M | ||
| Q1 25 | $206.1M | $-205.9M | ||
| Q4 24 | $200.0M | $-186.0M | ||
| Q3 24 | $196.1M | $-159.6M | ||
| Q2 24 | $194.7M | $-132.1M | ||
| Q1 24 | $192.1M | $-169.0M |
| Q4 25 | $228.9M | $108.4M | ||
| Q3 25 | $222.6M | $96.2M | ||
| Q2 25 | $220.2M | $104.9M | ||
| Q1 25 | $223.9M | $127.7M | ||
| Q4 24 | $218.2M | $164.4M | ||
| Q3 24 | $208.1M | $189.5M | ||
| Q2 24 | $201.8M | $214.0M | ||
| Q1 24 | $206.0M | $204.5M |
| Q4 25 | — | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.1M | $-11.8M |
| Free Cash FlowOCF − Capex | $10.1M | — |
| FCF MarginFCF / Revenue | 43.0% | — |
| Capex IntensityCapex / Revenue | 4.1% | 0.0% |
| Cash ConversionOCF / Net Profit | 3.23× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-3.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.1M | $-11.8M | ||
| Q3 25 | $-275.0K | $-5.9M | ||
| Q2 25 | $-23.9M | $-18.7M | ||
| Q1 25 | $12.4M | $-39.0M | ||
| Q4 24 | $14.8M | $-25.8M | ||
| Q3 24 | $-3.2M | $-19.5M | ||
| Q2 24 | $-1.0M | $-38.5M | ||
| Q1 24 | $11.7M | $-43.7M |
| Q4 25 | $10.1M | — | ||
| Q3 25 | $-1.3M | — | ||
| Q2 25 | $-24.4M | — | ||
| Q1 25 | $12.3M | — | ||
| Q4 24 | $14.5M | $-25.9M | ||
| Q3 24 | $-3.3M | — | ||
| Q2 24 | $-1.4M | — | ||
| Q1 24 | $11.7M | $-43.9M |
| Q4 25 | 43.0% | — | ||
| Q3 25 | -6.8% | — | ||
| Q2 25 | -90.4% | — | ||
| Q1 25 | 32.2% | — | ||
| Q4 24 | 46.1% | -84.7% | ||
| Q3 24 | -15.8% | — | ||
| Q2 24 | -5.6% | — | ||
| Q1 24 | 28.7% | -132.6% |
| Q4 25 | 4.1% | 0.0% | ||
| Q3 25 | 5.4% | 0.0% | ||
| Q2 25 | 1.8% | 0.0% | ||
| Q1 25 | 0.4% | 0.0% | ||
| Q4 24 | 1.0% | 0.2% | ||
| Q3 24 | 0.4% | 0.0% | ||
| Q2 24 | 1.5% | 0.0% | ||
| Q1 24 | 0.0% | 0.6% |
| Q4 25 | 3.23× | — | ||
| Q3 25 | -0.14× | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | 2.04× | — | ||
| Q4 24 | 3.88× | — | ||
| Q3 24 | -2.22× | — | ||
| Q2 24 | -0.41× | -1.62× | ||
| Q1 24 | 1.87× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GENC
Segment breakdown not available.
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
